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Summary
Objectives: To detail and put into perspective safety of hexaminolevulinate blue light
cystoscopy (HAL-BLC), including repeated use, based on combined data of
controlled trials used for registration of HAL and post-marketing experience.
Methods: Safety data of two randomized comparative studies (group 1) and four
within patient control studies (group 2) were combined. Post marketing data from
>200,000 patients were analyzed.
Results: In group 1, 533 patients were examined with HAL-BLC and 499 with white
light (WL) cystoscopy. In group 2, 791 patients were examined with both WL and
HAL-BLC. Between 73% and 93% of these patients had concomitant diseases.
Between 41% and 58% of patients had at least one adverse event (AE), although
predominantly mild to moderate. The majority was considered as not related to HALBLC and reported in the urinary tract. No SAEs were considered definitely related to
HAL-BLC, but in 6 patients serious AEs were of an uncertain relationship. Four
possibly related hypersensitivity reactions have been reported. Repeated use did not
reveal additional toxicity, also supported by data from three European centers.
Conclusions: This combined and detailed analysis of patients from 6 HAL-BLC
studies with very comparable criteria shows that HAL-BLC is safe and poses very
little additional risks other than expected for WL cystoscopy for bladder tumor
resection in this specific patient population. This is supported by 9 years of post
marketing experience. Repeated use also seems safe.
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Introduction

There have been only few new developments in the diagnosis and treatment of
bladder cancer in recent decades. For example, in the treatment of non muscleinvasive bladder cancer (NMIBC) Bacille Calmette-Guérin (BCG) was registered in
the mid eighties. If therapy was very effective this would not be a major issue.
However, recurrence rates in NMIBC are as high as 80% in high risk patients after
some years, thus creating an urgency to improve management [1].
In the last decade blue light cystoscopy (BLC) has become standard of practice in
many centres. BLC is done with hexaminolevulinate (HAL), which has been
registered for this indication. HAL blue light cystoscopy (BLC) has proven to detect
more bladder tumours, enabling a better tumour resection and better patient
management. These effects result in a lower short term and long term recurrence
rate of NMIBC [2-10]. A recent systemic review showed that 20% more patients with
papillary tumors were detected, and 39% more CIS patients [2]. This resulted in less
residual tumor (odds ratio 0.28) and a higher recurrence free survival (p=0.00002).
Based on the reduction in long term recurrence rate [10] the registered indication of
this drug changed from a pure detection tool to a drug that improves diagnosis and
management of bladder cancer patients. The European Association of Urology (EAU)
guideline recommends BLC in certain cases of (suspected) NMIBC [11]. In all, the
effectiveness of HAL-BLC is clearly proven.
Safety of HAL-BLC has been registered in all studies and BLC with HAL is
considered safe and well tolerated. Some of these data have also been reported in
the publications of these studies [3-9]. Since a favorable safety profile is an additional
reason to embrace on a new drug or technique when improved effectiveness is
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proven, this report specifically addresses the safety of HAL-BLC, including repeated
use.
This safety summary provides a review of detailed safety data collected in
6 controlled clinical trials conducted with HAL powder for solution, which were the
basis for the FDA approval 2010. Information from post-marketing experience is also
presented.

Patients and Methods

Six controlled studies were used for this safety analyses and review. Details and
results of these studies have been published before [3-9]. For all centers in these 6
studies Ethics Committee approval was obtained and for all patients informed
consent was obtained. Patient selection and treatment is very similar in all 6 studies.
All studies used a single dose HAL 8-mM solution. Cystoscopy was done with the
Karl Storz PDD D-light System. In all studies patients had a resection of papillary
tumors or biopsies of suspicious area’s seen during white light (WL) or BLC.
Four studies were within patient control studies (B201/00, B301/01, B302/01,
B303/01), so in these studies all patients had HAL-BLC as well as WL cystoscopy.
Studies B304/04 and B305/04 were randomized comparative studies, where patients
were randomized to have the inspection and transurethral resection of a tumor
(TURB) with WL, or HAL-BLC after WL.
Because the six controlled clinical studies were very comparable, safety data were
combined to study the safety profile of HAL-BLC in detail in this patient population.
AEs definitions and description of baseline voiding were the same throughout the six
studies. AEs were assessed from the time of HAL instillation until exit from the study.
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Treatment-emergent adverse events (TEAEs) were defined as those events that
occurred or worsened after exposure had begun. For patients in studies B305/04 and
B304/04 who were randomized to the standard cystoscopy arms, TEAEs were events
that occurred or worsened after the initiation of the standard cystoscopy procedure.
AEs considered by the investigator to be related to HAL-BLC with a high degree of
certainty or AEs where a relationship to HAL-BLC could not be ruled out are
presented together as “related AEs.” In the 305 extension study, thirty-nine out of
551 participants (both in the BLC and in the WL group) had multiple HAL instillations
after the initial study period. Data on possible anaphylactic reactions with repeated
use was collected retrospectively. Postmarketing data from the product approved in
2004 was also analysed.

Results

Efficacy
As mentioned above, results of these 6 studies have been published before [3-9]. In
short, all 6 studies showed significant increased detection rate with HAL-BLC,
especially for CIS. Two studies also looked at recurrence rate as endpoint. Both
studies showed an advantage for patients treated with HAL-BLC [3,4].

Safety
The studies combined for the safety analysis have been grouped as follows: in group
1 patients are included who received HAL-BLC (n=533) or WL (n=499) cystoscopy in
studies B305/04 and B304/04. In group 2, 791 patients are included from the 4 older
studies (B201/00, B301/01, B302/01, B303/01) in which patients had HAL-BLC after
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WL cystoscopy during the same procedure and anesthesia. In group 1 the median
age of the WL study group was 69.5, compared to 69.0 in the HAL-BLC group. In
group 2 median age was 68.5. Patients in all studies were primarily white and the
male female ratio was 3.2:1. The patient population appeared homogenous across
all six studies. Although the majority of patients had recurrent tumors, most had not
received intravesical therapy before.
As expected in a group of bladder cancer patients with advanced age, multiple co
morbidities and concomitant medications were noted. In group 1, 86.8% of patients in
the HAL-BLC study group and 73.3% of patients in the WL study group suffered from
ongoing diseases, as compared with 93% of patients in group 2. Baseline bladder
symptoms, noted and registered at study entry, are shown in table 1.
The safety evaluations that were performed in each of the six studies are listed in
table 2. Data from individual studies were pooled to create integrated data sets for
each of the data domains.
An overview of results in the different groups is presented below. In table 3 the
number of AEs is listed, whether the AEs are considered related, the number of AEs
leading to treatment discontinuation, the number of SAEs and finally the number of
deaths occurring during the study period. AEs per body system are detailed per
degree of severity in tables 4 (HAL-BLC versus WL in group 1) and 5 (group 2). As
expected, the most frequently involved body system in patients treated for bladder
cancer is the urinary tract. The second most frequently involved body organ system
was the gastrointestinal tract. AEs based on laboratory changes were rare, usually
mild and none was considered related to HAL-BLC. Also no unexpected findings or
adverse trends were apparent in vital signs or physical examination findings after
treatment with HAL-BLC. No trends for increased toxicity have been noted in patients
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whose instillation time exceeded the 1-hour period in the labeling. Mean HAL
retention time was 88.4 minutes (range: 4.0 to 360.0 minutes), and exceeded 180
minutes in 31 patients (table 6).
No SAEs were considered definitively related to HAL-BLC in any clinical study.
However, 8 SAEs observed in 6 patients were of an uncertain relationship to HALBLC. Treatment discontinuation due to an AE was reported in 12 (0.9%) of the total
of 1,324 patients. In group 1 eight BLC patients and one WL-cystoscopy patient were
withdrawn from study participation because of an AE (considered all serious per
protocol), none of which were considered to be related to HAL or WL exposure. In
group 2, 3 patients were withdrawn from study participation because of an SAE. Two
of these SAEs, in 1 patient, had an uncertain relationship to HAL exposure.
For this locally administered product, no apparent drug-drug, drug-food, or
drug-disease interactions were observed.
Overall, 21 patients died in these 6 studies (table 3). No deaths were attributable to
HAL-BLC.
Repeated use was studied in the long term follow up of controlled trial B305/04
(B305/E10). In the 4.5 years of follow up 29 of 128 European patients randomized to
HAL-BLC received repeated HAL from commercial source at a repeat TURB.
Thirteen patients had 1 additional TURB with HAL, 8 patients 2 additional HALTURBs and 8 patients underwent ≥3 additional TURBs with HAL. Of the 131
European patients in the WL group, 15 patients underwent 1 additional HAL-TURB, 4
patients underwent 2 additional HA-TURBs and 6 patients underwent ≥3 additional
HAL-TURBs. In total 39 patients were exposed to HAL at least twice during the study
period. All files were checked retrospectively, and no adverse events suggesting
anaphylaxis were found.
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Comment

AE’s into perspective. Although a summary of the AEs in the six individual studies
has been presented in the respective publications [3-9], this detailed analysis makes
it possible to put the AEs into the perspective of symptoms seen in bladder cancer
and this specific older patient cohort. NMIBC is associated with hematuria in 80% to
90% of patients [12-14]. Other less frequent signs are urinary frequency, dysuria and
pain, and a range of other renal or urinary tract related problems. This is confirmed
by data collected at study entry on bladder symptoms, before any manipulation had
taken place. As can be seen in table 1, already 20% to 30% of patients have
symptoms of the urinary tract at presentation. Another potential confounder in
bladder cancer patients, which are older and often still smoking, is frequent
competing co morbidities and concomitant medication. Indeed, nearly all patients
included in this clinical program used a number of concomitant medications. These
presenting symptoms and symptoms due to co morbidities should be distinguished
from symptoms due to diagnosis, treatment and surveillance of bladder cancer, since
obviously invasive procedures like cystoscopy, bladder biopsy, TURB and
cauterization can cause similar symptoms. Although this is daily practice for any
urologist, literature on quantitative analysis of typical complications occurring after
cystoscopy with rigid scopes and biopsies or TURB are very sparse. The
complications after flexible cystoscopy are better reported, and even flexible
cystoscopy is reported to cause urgency and increased voiding frequency in 35% to
40% of patients, and complaints of pain are reported in 20% to 50% of patients
[16,17]. Compared to our study, where rigid cystoscopy and TUR are applied,
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procedural pain and other urinary disorders and are found in approximately 5% and
25% after HAL-BLC and WL (table 4), and in 11.9% and 33.6% in those patients
were HAL-BLC and WL were combined (table 5). Also other symptoms in our study
are comparable or less as reported in literature. The frequency of urinary tract
infections in our study is comparable to that after cystoscopy only [16-19]. Our overall
frequency of hematuria after cystoscopy and TURB was 13.7%, compared to
reported gross hematuria after flexible cystoscopy in 19% [17]. In all, since symptoms
after rigid cystoscopy are reported twice as frequent compared to flexible cystoscopy
[20], this puts symptoms in our studies in a positive perspective, having used rigid
instruments in all studies.

Type of AE’s and relation to the procedure. Most frequent AEs were renal and urinary
disorders as expected [21], followed by gastro-intestinal AEs, procedural pain and
urinary tract infection. Type and frequency of AEs were comparable between HALBLC and WL cystoscopy in the two randomized studies and more frequently reported
when BLC and WL cystoscopy were combined. Most of these AEs were mild to
moderate. In patients receiving HAL-BLC, 79.8% of side effects had an onset during
or after the cystoscopic examination and were unrelated to HAL-BLC, which is given
more than one hour earlier. Similarly, in the WL study group, 87.2% AEs occurred
during or after the cystoscopic examination. Overall, HAL instillation was associated
with a low incidence of AEs that were considered by the investigator to be related to
the study product (table 3). The percentage of SAEs was somewhat different
between groups. The WL group in group 1 was in between these groups. SAEs were
uncommon and none were definitely related to HAL-BLC. Treatment discontinuation
due to an AE was also uncommon (0.9%) and not considered to be related to HAL
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exposure, except two AEs in one patient where the relationship with HAL-BLC was
considered uncertain. Overall, 21 patients died in these 6 studies which was
expected in view of the population of elderly patients with multiple concomitant
diseases.
In all, when compared with the AE data in the WL study group, and considering
baseline bladder cancer symptoms, concomitant disorders and discomfort due to the
treatment, the analysis of the AE data in the HAL-BLC study group does not indicate
significant risk beyond the current standard of care. The difference between group 1
and group 2 is likely due to the fact that in the initial 4 studies patients had a WL
cystoscopy followed by BLC. This results in an overall longer procedural time.

BLC and concomitant disorders. Although there was a high prevalence of
cardiovascular disease in the studied population (51.4% of HAL-BLC patients and
47.1% WL-cystoscopy patients presented with ongoing vascular disorders and 30.8%
of HAL-BLC and 27.1% WL-cystoscopy with ongoing cardiac disorders at baseline),
there were no findings to indicate that HAL-BLC contributed to cardiovascular risk in
individual patients.
With regard to laboratory changes these were uncommon and predominantly mild.
An increase in white blood cell counts might very well be a sign of urinary tract
infection due to the procedure or even a reactive rise due to the procedure itself.
Anemia obviously can be secondary to some bleeding after TURB. Slight decreases
in hemoglobin may also be caused by an increased plasma volume in patients who
were fasting and slightly dehydrated before the procedure and were rehydrated after
the procedure. Although reported in other studies [22], we found no relationship
between demographic factors and AEs. Finally the absence of increased toxicity in

11

case of higher or longer exposure to the drug and the safety profile in the post
marketing period confirms the safety profile of HAL-BLC.

Repeated use. An interesting issue is the repeated use of HAL. Repeated use of HAL
can be expected and is done because of the fact that NMIBC frequently recurs, with
subsequent repeated TURB’s. Prospective information on this issue is not available,
but it has been studied retrospectively in 39 European patients in the long term follow
up study B305/E10 where no adverse events suggesting anaphylaxis were found.
Additionally, collection of data from 3 hospitals which have used HAL repeatedly
(University Hospital, Tübingen, Germany, University Hospital, Regensburg, Germany
and Guy’s Hospital, London, UK), showed no anaphylactic reactions via the post
marketing reporting system (personal communication). The system contains data on
917 patients, 210 (23%) of which had more than one, and 70 (8%) had more than
two and up to six instillations of HAL during diagnosis and follow up of their bladder
cancer. Finally, postmarketing experience reflects the experience in more than
200,000 procedures with HAL-BLC over an 9 year period in 28 European countries
and now in the USA. Between September 17, 2004 and June 12, 2013, there were a
total of 27 reports of adverse drug reactions that have been received by the
Marketing Authorization Holders. For two reported anaphylactoid reactions and two
other cases of possible hypersensitivity reactions, a causal role of HAL-BLC could
not be ruled out. Both reported anaphylactic reactions were in patients that had their
first HAL instillation. The first report was in a 69 year old male. Five hours after the
instillation, which had a 3 hours retention time, he experienced a fall in blood
pressure, urticaria, chest pressure, swelling of the throat and atrial fibrillation. His
serum tryptase (a marker of mast cell activation) increased 9 times, and later his skin
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test was positive to HAL in duplicate. The mechanism remains uncertain, but it was
reported to be likely a non IgE mediated allergic reaction caused by HAL [23]. A
second event was a spontaneous report of an anaphylactoid shock in a 71 year old
male. Within 2 minutes, hypotension and exanthema developed, with a subsequent
coronary event due to the hypotension. He had a negative IgE enzyme immunoassay
test to concomitant ATB, and his serum tryptase was normal, although done 5 days
later. Whether this reaction was due to HAL-BLC or anesthetic medication remains
unclear. The other reported adverse reactions were attributed to manifestations of
underlying diseases or procedural complications.

Limitations. A limitation of this study might be that data from six individual trials were
combined. However, patient selection, characteristics and treatment, including the
HAL-BLC procedure, were very similar throughout the six studies. Also, registration
and definition of AEs remained the same. Indeed, the six individual datasets showed
comparable adverse event spectra. Laboratory changes, vital signs and physical
examination were not registered in all trials, but since they were uncommon and
predominantly mild, it seems unlikely that more data would have given another
spectrum of abnormalities.

Conclusion

In addition to the already published safety data of the six individual studies, the
detailed analysis on safety of this large combined data set, enhanced by 8 years of
post marketing experience, shows that HAL-BLC is safe and well tolerated and
poses very little additional risks in patients with known or suspected bladder cancer.
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There were no signs that HAL-BLC contributed to the frequency or severity of AEs,
other than what could be expected for WL cystoscopy, for TURB procedures and in
this patient population. Except for 4 possible cases of hypersensitivity reactions , no
particular clusters of any particular post marketing reactions have been received.
Repeated use also seems safe. On the other hand there is little discussion on the
improved patient’s outcome after HAL TURB. This suggests a positive medical risk
benefit ratio, which might stand up to other strategies to improve patient’s outcome
with intravesical drug therapy.
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Table 1: Bladder symptoms at study entry in the safety set, when recorded.
Group 1
HAL (n=533)
n (%)

WL (n=499)
n (%)

Group 2
HAL (n=791)
n (%)

Hematuria
Yes
48 (9.0%)
34 (6.8%)
134 (16.9%)
No
372 (69.8%)
346 (69.3%)
655 (82.8%)
Missing
0 (0.0%)
0 (0.0%)
2 (0.3%)
Painful urination
Yes
21 (3.9%)
17 (3.4%)
60 (7.6%)
No
399 (74.9%)
363 (72.7%)
729 (92.2%)
Missing
0 (0.0%)
0 (0.0%)
2 (0.3%)
Frequent Urination or the Urge to Urinate, but without Results
Yes
45 (8.4%)
46 (9.2%)
158 (20.0%)
No
374 (70.2%)
334 (66.9%)
631 (79.8%)
Missing
1 (0.2%)
0 (0.0%)
2 (0.3%)
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Table 2. Safety evaluations performed per study
Evaluations

B201/00 B301/01 B302/01 B303/01 B304/04 B305/04

Adverse events*
X
X
X
X
X
X
Hematology and
X
X
X
biochemistry†
Vital signs‡
X
X
X
X
Physical examination‡
X
X
X
X
Concomitant
X
X
X
X
X
X
medications§
*
Adverse events were monitored throughout the study.
†
Blood samples were collected before Hexvix instillation and at 24 hours after.
‡
Evaluations were performed before Hexvix instillation and at 24 hours after.
§
Concomitant medications were monitored and recorded throughout the followup phase of each study.
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Table 3: Overview of AEs experienced in the 6 controlled studies (safety set)

Total number of unique AEs
Patients with at least one AE (n [%])

Group 1
HAL
N = 533
599
232
(43.5%)

WL
N = 499
494
204
(40.9%)

Total number of unique related
56
1
AEs§
Patients with at least one related AE
38 (7.1%) 1 (0.2%)
(n [%])
Total number of unique AEs leading
to discontinuation
Patients with at least one AE
leading to discontinuation (n [%])
Total number of unique SAEs
Patients with at least one SAE (n
[%])

Group 2
HAL
N = 791
1,181
457 (57.8%)

232
123 (15.5%)

8

1

4

8 (1.5%)

1 (0.2%)

3 (0.4%)

63

47

57

51 (9.6%) 36 (7.2%) 47 (5.9%)

Deaths occurring during the study
10 (1.9%) 4 (0.8%)
7 (0.9%)
period║
Note: Patients with multiple AEs under one preferred term or body system are
counted only once in the most severe category for that preferred term or body
system. If one event is related to exposure and another is not related, the related AE
is counted.
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Table 4. Summary of most frequent AEs by severity in group 1
HAL, N = 533
MedDRA Body
System
Preferred Term
Total number of
unique AEs occurring
in at least 1% of the
safety set across
studies
Patients with at least
one AE

Gastrointestinal
disorders*

Urinary tract infection

Procedural pain

Renal and urinary
disorders**

*

WL, N = 499

Mild
n (%)

Moderat
e, n (%)

Seve
re, n
(%)

Sum
n (%)

Mild
n (%)

Modera
te, n %)

Sever
e,
n(%)

Sum
n (%)

201

145

15

361

176

113

5

294

77
(14.4%
)

87
(16.3%)

15
(2.8
%)

179
84
71
(33.6% (16.8%
(14.2%)
)
)

5
(1.0%
)

160
(32.1
%)

24
(4.5%)

11
(2.1%)

1
(0.2
%)

36
(6.8%)

21
(4.2%)

12
(2.4%)

1
(0.2%
)

34
(6.8%
)

16
(3.0%)

11
(2.1%)

1
(0.2
%)

28
(5.3%)

15
(3.0%)

10
(2.0%)

0
(0.0%
)

25
(5.0%
)

13
(2.4%)

15
(2.8%)

0
(0.0
%)

28
(5.3%)

13
(2.6%)

7
(1.4%)

0
(0.0%
)

20
(4.0%
)

63
(11.8%
)

62
(11.6%)

12
(2.3
%)

52
61
137
(25.7% (12.2% (10.4%)
)
)

4
(0.8%
)

117
(23.4
%)

Including abdominal pain, constipation, diarrhea, nausea and vomiting

**
including bladder pain, bladder perforation, bladder spasm, dysuria,
hematuria, micturition urgency, pollakiuria and urinary retention
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Table 5 Summary of most frequent AEs in group 2
Group 2*
HAL, N = 791
Mild
Moderate
n (%)
n (%)

Severe
n (%)

Sum
n (%)

483

271

28

782

211 (26.7%)

161
(20.4%)

26
(3.3%)

398 (50.3%)

Gastrointestinal
disorders*

56 (7.1%)

36
(4.6%)

2 (0.3%) 94 (11.9%)

Urinary tract infection

12 (1.5%)

9 (1.1%)

1 (0.1%) 22 (2.8%)

Procedural pain

59 (7.5%)

34 (4.3%)

1 (0.1%) 94 (11.9%)

Renal and urinary
disorders**

158 (20.0%)

91 (11.5%)

17
(2.1%)

MedDRA Body System
Preferred Term
Total number of unique
AEs occurring in at least
1% of the safety set
across studies
Patients with at least
one AE

*

266 (33.6%)

Including abdominal pain, constipation, diarrhea, nausea and vomiting

**
including bladder pain, bladder perforation, bladder spasm, dysuria,
hematuria, micturition urgency, pollakiuria and urinary retention
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Table 6: HAL mean retention times

Study
[reference]
B201/00 [5]
B301/01 [6]
B302/01 [7,8]
B303/01 [9]
B304/04 [4]
B305/04 [3]

Mean retention time in minutes (min
and max)
86.2 (45-229)
85.7 (5-343)
87.0 (34-210)
82.4 (10-360)
102.7 (12-303)
90.3 (4-255)

Patient number
52
278
297
162
109
410
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